TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer

Molecular Endocrinology

Volumn 26, Issue 5, 2012, Pages 748-761

  Takayama, Ken Ichi ^a,b   Horie Inoue, Kuniko ^b   Suzuki, Takashi ^d   Urano, Tomohiko ^a,b   Ikeda, Kazuhiro ^b   Fujimura, Tetsuya ^a   Takahashi, Satoru ^c   Homma, Yukio ^a   Ouchi, Yasuyoshi ^a   Inoue, Satoshi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL CYCLE PROTEIN; TRANSFORMING ACIDIC COILED COIL PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INDUCTION; HUMAN; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; TACC 2 GENE;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANIMALS; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84860350749     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1242     Document Type: Article

References (44)

1. Dehm SM, Tindall DJ 2006 Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99:333-344
2. Debes JD, Tindall DJ 2004 Mechanism of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490.
3. Suzuki H, Ueda T, Ichikawa T, Ito H 2003 Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10:209-216
4. Balk SP, Knudsen KE 2008 AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
6. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
7. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319
8. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T 2009 Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141-8149
9. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392
10. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
11. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256
12. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H, Inoue S 2007 Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26:4453-4463
13. Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, Takahashi S, Kitamura T, Ouchi Y, Aburatani H, Inoue S 2009 Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 69: 137-142
14. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A, Ikeo K, Gojyobori T, Ouchi Y, Hayashizaki Y, Aburatani H, Inoue S 2011 Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30:619-630
15. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vallaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette Y, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM 2010 An integrated network of androgen receptor, polycomb, and TMPRSS2- ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454
16. Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y, Ouchi Y, Inoue S 2008 FOXP1 is an androgenresponsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 374:388-393
17. Tei S, Saitoh N, Funahara T, Iida S, Nakatsu Y, Kinoshita K, Kinoshita Y, Saya H, Nakao M 2009 Simian virus 40 large T antigen targets the microtubule-stabilizing protein TACC2. J Cell Sci 122:3190-3198
18. Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW 2000 The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci USA 97:14352-14357
19. Peset I, Vernos I 2008 The TACC proteins: TACC-ling microtubule dynamics and centrosome function. Trends Cell Biol 18:379-388
20. Chen HM, Schmeichel KL, Mian IS, Lelièvre S, Petersen OW, Bissell MJ 2000 AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. Mol Biol Cell 11:1357-1367
21. Lauffart B, Gangisetty O, Still IH 2003 Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2. Genomics 81:192-201
22. Cheng S, Douglas-Jones A, Yang X, Mansel RE, Jiang WG 2010 Transforming acidic coiled-coil-containing protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance. Cancer Genomics Proteomics 7:67-73
23. Gangisetty O, Lauffart B, Sondarva GV, Chelsea DM, Still IH 2004 The transforming acidic coiled coil proteins interact with nuclear histone acetyltransferases. Oncogene 23:2559-2563
24. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H 1999 Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251
25. Kokontis J, Takakura K, Hay N, Liao S 1994 Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573
26. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O 2006 Requirement of androgen-dependent activation of protein kinase Cζ for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol Endocrinol 20: 3053-3069
27. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S 2009 Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 69:2935-2940
28. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D 2002 The human genome browser at UCSC. Genome Res 12:996-1006
29. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H 2007 Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-mediated invasion and potent prognostic factor. Endocr Relat Cancer 14:279-292
30. Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ 2011 Androgen receptor amplification is reflected in the transcriptional responses of vertebral-cancer of the prostate cells. Mol Cell Endocrinol 331:57-65
31. Obinata D, Takayama K, Urano T, Ikeda K, Horie-Inoue K, Ouchi Y, Takahashi S, Inoue S 6 June 2011 ARFGAP3, an androgen target gene, promotes prostate cancer cell proliferation and migration. Int J Cancer. 10.1002/ijc. 26224
32. Cully M, Shiu J, Piekorz RP, Muller WJ, Done SJ, Mak TW 2005 Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. Cancer Res 65:10363-10370
33. Still IH, Vince P, Cowell JK 1999 The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 58:165-170
34. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH 2005 Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Women's Health 5:8
35. Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY 2006 Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int 56:503-509
36. Conte N, Delaval B, Ginestier C, Ferrand A, Isnardon D, Larroque C, Prigent C, Séraphin B, Jacquemier J, Birnbaum D 2003 TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene 22: 8102-8116
37. Yuan X, Balk SP 2009 Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27:36-41
38. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
39. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y 2006 2006 Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10:309-319
40. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Colema IM, Nguyen HM, Sun H, Nelson PS, Plymate SR 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-2730
41. Bjartell A, Montironi R, Berney DM, Egevad L 2011 Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 50 (Suppl 1):76-84
42. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS 2009 Ki-67 and outcome in clinically localized prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100: 888-893
43. Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L, Rehg J, Ihle JN 2002 The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 21:653-664
44. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Schulze-Osthoff K, Nürnberg B, Piekorz RP 2008 TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene 27:116-125